# US 2025/0144045 A1 · Tetrabenazine transdermal delivery device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144045 A1
- Document ID: US20250144045A1
- Status: Published application
- Kind: A1
- Application number: 18/911,581
- Filed: 2024-10-10
- Published: 2025-05-08
- Earliest claimed: 2018-04-25
- Assignees: Shinkei Therapeutics, Inc.
- Applicants: Shinkei Therapeutics, Inc.
- Inventors: Suresh BORSADIA; Kalpana PATEL; Hock S. TAN
- Web page: https://patentgrep.com/patent/US20250144045A1

## CPC

- A61K 9/7061: {Polyacrylates}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are transdermal delivery devices comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof. Also provided herein are pharmaceutical compositions, such as adhesive compositions, comprising tetrabenazine, a deuterated tetrabenazine, or a combination thereof, for example, homogenously dispersed in an adhesive, such as a pressure sensitive adhesive. Further provided herein are methods of using the transdermal delivery devices or pharmaceutical compositions, for example, for treating a hyperkinetic movement disorder.

## Claims

### Claim 1

An adhesive composition comprising:
an active ingredient dispersed in a non-reactive acrylate pressure sensitive adhesive,
wherein the active ingredient is selected from tetrabenazine, deuterated tetrabenazine, or a combination thereof,
wherein the non-reactive acrylate pressure sensitive adhesive is in an amount of about 50% to about 97% by weight.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The adhesive composition of claim 1, wherein the non-reactive acrylate pressure sensitive adhesive is a copolymer of hexylethyl acrylate and methyl acrylate, and optionally one or more acrylamide monomers with no functional groups selected from epoxy, —OH, —COOH, and combinations thereof.

### Claim at position 4

-10. (canceled)

### Claim 11 (depends on 1)

The adhesive composition of claim 1, wherein the active ingredient is present in an amount of about 2% to about 7% by weight.

### Claim 12 (depends on 1)

The adhesive composition of claim 1, further comprising a gallate antioxidant.

### Claim 13 (depends on 1)

The adhesive composition of claim 1, further comprising propyl gallate in an amount of about 0.001% to about 0.5% by weight.

### Claim 14 (depends on 1)

The adhesive composition of claim 1, further comprising a crystallization inhibitor in an amount effective to prevent formation of drug crystals after shelf storage for two weeks at ambient temperature.

### Claim 15 (depends on 1)

The adhesive composition of claim 1, further comprising a crystallization inhibitor selected from a polyvinylpyrrolidone polymer, a cross-linked polyvinylpyrrolidone polymer, a polyvinylpyrrolidone copolymer, a cellulose based polymer, a polycarboxylic acid polymer, a polymethacrylate, a polyethylene glycol, polyvinyl acetate and polyvinylcaprolactame-based graft copolymer (PVAc-PVCap-PEG), and combinations thereof.

### Claim 16 (depends on 1)

The adhesive composition of claim 1, further comprising a crystallization inhibitor selected from a polymethacrylate, a polyethylene glycol, polyvinyl acetate and polyvinylcaprolactame-based graft copolymer (PVAc-PVCap-PEG), and combinations thereof.

### Claim 17 (depends on 1)

The adhesive composition of claim 1, wherein the sole active ingredient is a substantially pure R,R-isomer of tetrabenazine.

### Claim 18 (depends on 1)

The adhesive composition of claim 1, which is capable of adhering continuously to the skin of a user for about 8 hours, about 12 hours, about 18 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days or more.

### Claim 19 (depends on 1)

A transdermal delivery device comprising:
a backing layer,
the adhesive composition of claim 1; and
a release liner.

### Claim 20 (depends on 19)

The transdermal delivery device of claim 19, which is shelf stable.

### Claim 21 (depends on 19)

The transdermal delivery device of claim 19, which provides a subject user the active ingredient at a rate of about 0.01 mg/day/cm2 to about 5 mg/day/cm2, e.g., for a period of about 8 hours, about 12 hours, about 18 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days or more.

### Claim at position 16

-24. (canceled)

### Claim 25 (depends on 1)

A method of inhibiting a vesicular monoamine transporter isoform 2 (VMAT2) in a subject in need thereof, the method comprising applying the adhesive composition of claim 1 to the skin of the subject.

### Claim 26 (depends on 1)

A method of treating a vesicular monoamine transporter isoform 2 (VMAT2) mediated disease or disorder in a subject in need thereof, the method comprising applying the adhesive composition of claim 1 to the skin of the subject.

### Claim 27 (depends on 1)

A method of treating a hyperkinetic movement disorder in a subject in need thereof, comprising applying the adhesive composition of claim 1 to the skin of the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the hyperkinetic movement disorder is a chronic hyperkinetic movement disorder.

### Claim 29 (depends on 27)

The method of claim 27, wherein the hyperkinetic movement disorder is chorea associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, tardive dyskinesia, and/or a tic.

### Claim 30

A method of treating a hyperkinetic movement disorder in a subject in need thereof, the method comprising transdermally administering a therapeutically effective amount of tetrabenazine or deuterated tetrabenazine to the subject.
